January 12, 2009 7:31 a.m. EST
Miami, FL (AHN) – Federal regulators approved the use of a controversial drug to treat high cholesterol last week.
The Food and Drug Administration gave Vytorin the OK a year after a study came out suggesting it wasn’t any more effective than Zocor in lowering bad cholesterol.
Vytorin is a combination of simvastatin, the generic name for Zocor, and ezetimibe.
But now the FDA said a recent trial found a 56-percent Read the rest of this entry »

The US Food and Drug Administration has given marketing approval to a new drug that lowers levels of uric acid in the blood of patients with
gout: the current treatment for the condition was developed over 40 years ago. The new drug is called ULORIC (generic name febuxostat) and Takeda
Pharmaceuticals North America is the sole developer and marketer of the product in the US.
According to a statement from Takeda, febuxostat is a new highly potent Read the rest of this entry »

These gains don’t cause pain. A capital gain is the amount of money you pocket by selling one of your investments for more
than you paid for it. Technically, capital gains only count for what’s called a capital asset, but that’s really just anything
you own for investment purposes. Stocks and bonds obviously qualify, but your house and household furnishings can also count.
For
tax purposes, capital gains Read the rest of this entry »

For the first time in more than forty years there’s a new medication receiving FDA approval for the treatment of gout. 
That often affects one joint, which is most often the big toe, but can happen with many joints in the body.
It’s the most common inflammatory arthritis is men over age 40.
The medicine is called Uloric.
It’s a once daily oral medication that works by blocking an enzyme which helps prevent uric acid production, lowering uric Read the rest of this entry »

said Wednesday it received clearance from the Food and Drug Administration for its Pathiam System with iScan for assessment of HER2/neu immunohistochemistry tests.
Cupertino-based BioImagene said the scanner and associated software are used to detect and provide a quantitative measurement of HER2/neu, a protein that is measured in breast cancer patients in order to determine if they are candidates for treatment with the breast cancer drug Herceptin.
Read the rest of this entry »

Washington, D.C. – infoZine – The U.S. Food and Drug Administration licensed RiaSTAP, an orphan drug for the treatment of bleeding in patients with a rare genetic defect known as congenital fibrinogen deficiency. Without treatment, these patients are at risk of potentially life-threatening bleeding.
People with congenital fibrinogen deficiency are unable to make sufficient amounts of fibrinogen, which plays an important role in blood coagulation Read the rest of this entry »

Dec 22, 2008 (CIDRAP News) – The US Food and Drug Administration (FDA) recently approved a new version of BioThrax—the nation’s only licensed anthrax vaccine—that requires fewer doses and changes the injection route.
Emergent BioSolutions, maker of BioThrax, said in a Dec 19 press release that the FDA’s approval of the company’s supplemental biologics license application for its anthrax vaccine adsorbed (AVA) allows a new schedule Read the rest of this entry »

BEIJING, Dec. 29 (Xinhuanet) — The Food and Drug
Administration (FDA) recently approved the first drug that will help with
producing longer eyelashes, according to media reports Monday.
Latisse, produced by the company of Allergan, is
supposed to treat those who have hypotrichosis, a condition in which a person
does not have enough eyelashes. It will be available by prescription starting in
the first quarter of 2009.
The active ingredient Read the rest of this entry »

(NaturalNews) The FDA has approved 18 products for market from generic drug manufacturer Ranbaxy Laboratories, even though the company is currently being investigated by Congress for making substandard products and conspiring to fraudulently cover it up.
“Allegations from reliable sources and supporting documents indicate a pattern of systemic fraudulent conduct, including submissions by Ranbaxy to the FDA that contain false and fabricated information,” Read the rest of this entry »

For the first time in history, a drug produced from a genetically-engineered animal has won the approval of the Food and Drug Administration. The FDA on Friday gave its approval to the use of genetically-altered goats to produce a blood-clot preventing drug called antithrombin. The anti-clotting agent is manufactured by a herd of some 200 bioengineered goats on a carefully controlled farm in Massachusetts. The move by the FDA has had its fair share Read the rest of this entry »